VANCOUVER, BC – Acuitas Therapeutics announced the publication of a new study in Science Immunology, titled “An IL12 mRNA-LNP adjuvant enhances mRNA vaccine-induced CD8 T cell responses.” The study demonstrates… Read More
SOUTH SAN FRANCISCO, CA – Abdera Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable precision radiopharmaceuticals for cancer, announced the… Read More
Launch enables efficient and scalable electroporation across research applications up to GMP manufacturing New system includes optimized cartridge design for improved performance for CRISPR-based knock-out, knock-in and transposition BASEL, CH… Read More
Data from longer-term follow-up of patients in ongoing clinical trials further demonstrate durability of the clinical benefits of CASGEVY® Multiple reimbursement agreements secured, expanding access to CASGEVY to more patients… Read More
Pluvicto® now publicly funded in provinces covering most Canadians, offering renewed hope to those facing progressive PSMA-positive metastatic castration-resistant prostate cancer Momentum builds nationwide as more jurisdictions recognize radioligand as… Read More
